دورية أكاديمية
أعرض في EDS

Outsmarting trogocytosis to boost CAR NK/T cell therapy.

التفاصيل البيبلوغرافية
العنوان: Outsmarting trogocytosis to boost CAR NK/T cell therapy.
المؤلفون: Ramezani F; Division of Medical Biotechnology, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.; Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran., Panahi Meymandi AR; Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Akbari B; Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Tamtaji OR; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.; Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Mirzaei H; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran., Brown CE; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA, USA.; Department of Immuno-Oncology, City of Hope Beckman Research Institute, Duarte, CA, USA., Mirzaei HR; Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. h-mirzaei@tums.ac.ir.; Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. h-mirzaei@tums.ac.ir.
المصدر: Molecular cancer [Mol Cancer] 2023 Nov 16; Vol. 22 (1), pp. 183. Date of Electronic Publication: 2023 Nov 16.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2002-
مواضيع طبية MeSH: Receptors, Chimeric Antigen*/metabolism , Neoplasms*/metabolism, Humans ; Killer Cells, Natural ; Trogocytosis ; Immunotherapy, Adoptive ; T-Lymphocytes ; Cell- and Tissue-Based Therapy
مستخلص: Chimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors, including the phenomenon of trogocytosis, which involves the bidirectional exchange of membrane fragments between cells. In this review, we explore the role of trogocytosis in CAR NK/T cell therapy and highlight potential strategies for its modulation to improve therapeutic efficacy. We provide an in-depth analysis of trogocytosis as it relates to the fate and function of NK and T cells, focusing on its effects on cell activation, cytotoxicity, and antigen presentation. We discuss how trogocytosis can mediate transient antigen loss on cancer cells, thereby negatively affecting the effector function of CAR NK/T cells. Additionally, we address the phenomenon of fratricide and trogocytosis-associated exhaustion, which can limit the persistence and effectiveness of CAR-expressing cells. Furthermore, we explore how trogocytosis can impact CAR NK/T cell functionality, including the acquisition of target molecules and the modulation of signaling pathways. To overcome the negative effects of trogocytosis on cellular immunotherapy, we propose innovative approaches to modulate trogocytosis and augment CAR NK/T cell therapy. These strategies encompass targeting trogocytosis-related molecules, engineering CAR NK/T cells to resist trogocytosis-induced exhaustion and leveraging trogocytosis to enhance the function of CAR-expressing cells. By overcoming the limitations imposed by trogocytosis, it may be possible to unleash the full potential of CAR NK/T therapy against cancer. The knowledge and strategies presented in this review will guide future research and development, leading to improved therapeutic outcomes in the field of immunotherapy.
(© 2023. The Author(s).)
References: Eur J Med Chem. 2023 May 5;251:115240. (PMID: 36924670)
Cancer J. 2019 May/Jun;25(3):217-222. (PMID: 31135529)
Mol Cancer Res. 2020 Feb;18(2):229-239. (PMID: 31676721)
Cell Mol Life Sci. 2011 Oct;68(19):3275-92. (PMID: 21365281)
Nat Med. 2015 Jun;21(6):581-90. (PMID: 25939063)
J Leukoc Biol. 2006 Dec;80(6):1354-63. (PMID: 16980510)
J Immunol. 2001 Apr 15;166(8):5018-26. (PMID: 11290782)
Exp Biol Med (Maywood). 2021 May;246(9):1121-1138. (PMID: 33601913)
Immunol Rev. 2006 Oct;213:131-45. (PMID: 16972901)
J Immunol. 2010 Dec 1;185(11):6545-54. (PMID: 21048115)
Front Immunol. 2022 Feb 03;13:791006. (PMID: 35185886)
Physiol Rev. 2012 Jul;92(3):1005-60. (PMID: 22811424)
Front Immunol. 2018 Apr 30;9:863. (PMID: 29760699)
Cancer Res. 2021 Jun 1;81(11):3022-3035. (PMID: 33795251)
Cell Mol Immunol. 2012 Mar;9(2):136-46. (PMID: 22307040)
Front Cell Infect Microbiol. 2020 Feb 13;10:49. (PMID: 32117816)
Cell Rep. 2018 Jun 26;23(13):3946-3959.e6. (PMID: 29949776)
Cell. 2021 Dec 9;184(25):6081-6100.e26. (PMID: 34861191)
Nat Immunol. 2003 May;4(5):399-403. (PMID: 12719728)
Cancer Discov. 2018 Oct;8(10):1219-1226. (PMID: 30135176)
Mol Ther. 2009 Aug;17(8):1453-64. (PMID: 19384291)
FEBS Lett. 2009 Jun 5;583(11):1792-9. (PMID: 19289124)
PLoS One. 2007 Nov 21;2(11):e1204. (PMID: 18030338)
Blood. 2013 Apr 25;121(17):3396-401. (PMID: 23449637)
Biomolecules. 2023 Feb 10;13(2):. (PMID: 36830717)
Cancer Immunol Res. 2014 Aug;2(8):732-40. (PMID: 24934445)
J Immunol. 2001 Jul 15;167(2):875-83. (PMID: 11441094)
Nat Med. 2022 Oct;28(10):2133-2144. (PMID: 36175679)
Hum Immunol. 2016 Oct;77(10):876-885. (PMID: 27349945)
Mol Ther. 2017 Aug 2;25(8):1933-1945. (PMID: 28479045)
J Immunol. 2011 Feb 15;186(4):2148-55. (PMID: 21242518)
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18360-5. (PMID: 22042851)
PLoS One. 2010 Jan 14;5(1):e8716. (PMID: 20090930)
Front Immunol. 2023 Jan 19;13:1074644. (PMID: 36741387)
Eur J Immunol. 2013 May;43(5):1345-55. (PMID: 23440763)
Nat Rev Cancer. 2021 May;21(5):298-312. (PMID: 33750922)
J Immunol Res. 2015;2015:754373. (PMID: 25961063)
Leukemia. 2022 Jul;36(7):1943-1946. (PMID: 35490197)
Cancer Immunol Res. 2021 Jul;9(7):790-810. (PMID: 33990375)
J Leukoc Biol. 2015 May;97(5):909-919. (PMID: 25765680)
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):. (PMID: 34301886)
Oncoimmunology. 2022 Jun 28;11(1):2093426. (PMID: 35898704)
J Immunol. 2015 Feb 15;194(4):1945-53. (PMID: 25582853)
Front Immunol. 2017 Dec 22;8:1850. (PMID: 29312333)
Front Immunol. 2017 Feb 24;8:175. (PMID: 28286501)
Immunity. 2016 Feb 16;44(2):380-90. (PMID: 26885860)
N Engl J Med. 2020 Feb 6;382(6):545-553. (PMID: 32023374)
Cancer Discov. 2016 Feb;6(2):133-46. (PMID: 26503962)
Nat Med. 2019 Aug;25(8):1218-1224. (PMID: 31308506)
J Cell Physiol. 2019 Nov;234(11):21076-21088. (PMID: 31025383)
Nat Med. 2019 Sep;25(9):1408-1414. (PMID: 31477906)
J Immunother Cancer. 2022 Nov;10(11):. (PMID: 36323436)
Crit Rev Immunol. 2012;32(4):287-305. (PMID: 23237506)
MAbs. 2020 Jan-Dec;12(1):1688616. (PMID: 31852337)
Oncoimmunology. 2017 Oct 16;7(2):e1380764. (PMID: 29308300)
J Exp Med. 2000 Apr 3;191(7):1137-48. (PMID: 10748232)
Nat Commun. 2021 Feb 8;12(1):868. (PMID: 33558511)
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9421-6. (PMID: 23690625)
J Immunol. 2011 Mar 1;186(5):2765-71. (PMID: 21263069)
Science. 1999 Oct 29;286(5441):952-4. (PMID: 10542149)
J Immunol. 2001 Feb 15;166(4):2505-13. (PMID: 11160311)
J Immunol. 2007 Mar 15;178(6):3637-47. (PMID: 17339461)
Cell Mol Immunol. 2008 Aug;5(4):261-9. (PMID: 18761813)
J Immunol. 2002 Dec 1;169(11):6162-9. (PMID: 12444120)
Blood. 2003 Apr 1;101(7):2704-10. (PMID: 12433692)
J Immunol. 2001 Mar 15;166(6):3645-9. (PMID: 11238601)
Sci Adv. 2022 Apr 15;8(15):eabj3286. (PMID: 35417234)
Cell Metab. 2022 Sep 6;34(9):1342-1358.e7. (PMID: 36070682)
Elife. 2016 Jan 23;5:. (PMID: 26802627)
Clin Cancer Res. 2013 Apr 15;19(8):2048-60. (PMID: 23344265)
Immunity. 2003 Jan;18(1):41-51. (PMID: 12530974)
Blood. 2012 Sep 6;120(10):2055-63. (PMID: 22705596)
Cancer Cell. 2019 Jan 14;35(1):33-45.e6. (PMID: 30645975)
Cell Immunol. 2001 Nov 25;214(1):21-34. (PMID: 11902826)
Nature. 2002 Oct 17;419(6908):729-34. (PMID: 12384701)
Cells. 2021 May 19;10(5):. (PMID: 34069602)
Front Endocrinol (Lausanne). 2020 Aug 14;11:556. (PMID: 32922364)
Adv Immunol. 2003;81:199-252. (PMID: 14711057)
Nat Rev Immunol. 2015 Aug;15(8):486-99. (PMID: 26205583)
Gene Expr. 2010;15(1):1-11. (PMID: 21061913)
J Immunol. 2019 May 15;202(10):2873-2887. (PMID: 30962293)
Front Immunol. 2022 Oct 17;13:1032403. (PMID: 36325345)
J Immunol. 2012 Jan 15;188(2):744-52. (PMID: 22174448)
Blood. 2004 Jan 15;103(2):689-94. (PMID: 14512299)
Mol Ther Oncolytics. 2022 Mar 19;25:69-77. (PMID: 35434273)
Cancer Res. 2005 Nov 15;65(22):10139-44. (PMID: 16287995)
J Immunol. 2008 Feb 1;180(3):1309-15. (PMID: 18209024)
JCI Insight. 2019 Jun 18;5:. (PMID: 31211693)
N Engl J Med. 2019 May 2;380(18):1726-1737. (PMID: 31042825)
J Clin Invest. 2016 Apr 1;126(4):1216-23. (PMID: 26927673)
Cell Rep. 2021 Aug 31;36(9):109632. (PMID: 34469729)
Cell Rep. 2014 Aug 7;8(3):871-882. (PMID: 25088413)
Nat Immunol. 2003 Sep;4(9):815. (PMID: 12942076)
Cells. 2021 Jun 12;10(6):. (PMID: 34204661)
J Immunol. 2012 Nov 15;189(10):4728-39. (PMID: 23066151)
Oncoimmunology. 2013 Nov 1;2(11):e26529. (PMID: 24475374)
Hepatology. 2015 Sep;62(3):702-14. (PMID: 25999047)
Front Immunol. 2021 Dec 14;12:707542. (PMID: 34970253)
PLoS One. 2013 Dec 04;8(12):e81404. (PMID: 24324692)
Oncogene. 2021 Jan;40(2):421-435. (PMID: 33168929)
Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17608-17610. (PMID: 31481628)
J Immunother Cancer. 2021 Feb;9(2):. (PMID: 33526607)
EMBO J. 2007 Mar 7;26(5):1423-33. (PMID: 17318190)
Cancer Discov. 2013 Apr;3(4):388-98. (PMID: 23550147)
Front Immunol. 2023 Mar 31;14:1140623. (PMID: 37063836)
Proc Natl Acad Sci U S A. 2020 Dec 15;117(50):32105-32113. (PMID: 33239446)
J Immunol. 2005 Jun 15;174(12):7497-505. (PMID: 15944248)
Nature. 2019 Apr;568(7750):112-116. (PMID: 30918399)
Cells. 2021 May 10;10(5):. (PMID: 34068819)
Cancer Immunol Immunother. 2013 Jul;62(7):1137-48. (PMID: 23666510)
Nat Rev Immunol. 2014 Nov;14(11):731-43. (PMID: 25324126)
J Mol Med (Berl). 2016 May;94(5):489-95. (PMID: 26910191)
Vaccines (Basel). 2022 Oct 31;10(11):. (PMID: 36366354)
Annu Rev Immunol. 2013;31:227-58. (PMID: 23516982)
فهرسة مساهمة: Keywords: CAR NK cells; CAR T cells; Cancer immunotherapy; Trogocytosis
المشرفين على المادة: 0 (Receptors, Chimeric Antigen)
تواريخ الأحداث: Date Created: 20231117 Date Completed: 20231127 Latest Revision: 20240228
رمز التحديث: 20240229
مُعرف محوري في PubMed: PMC10652537
DOI: 10.1186/s12943-023-01894-9
PMID: 37974170
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-4598
DOI:10.1186/s12943-023-01894-9